Talisker Initiates Milling at Nicola’s Craigmont Mill

Talisker Initiates Milling at Nicola's Craigmont Mill GlobeNewswire July 07, 2025 TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company“) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that the Company has commenced milling and processing of run of mine material from Talisker's Mustang Mine (“Mustang”) at Nicola Mining Company's […]

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure GlobeNewswire July 07, 2025 In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025 GlobeNewswire July 07, 2025 Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection after a single dose TNX-801 is well tolerated in immunocompromised animals, without

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia GlobeNewswire July 07, 2025 Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 GlobeNewswire July 07, 2025 NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS)

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development GlobeNewswire July 07, 2025 WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief

Lancaster Strengthens Gold Portfolio with Completion of Lake Cargelligo Acquisition

Lancaster Strengthens Gold Portfolio with Completion of Lake Cargelligo Acquisition GlobeNewswire July 07, 2025 VANCOUVER, British Columbia, July 07, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (“Lancaster“, the “Company“) is pleased to announce the completion of its acquisition of 100% of the Lake Cargelligo Gold Project, a district-scale exploration property in

Western Financial Group Wins 2025 Canadian Business Excellence Award

Western Financial Group Wins 2025 Canadian Business Excellence Award Award recognizes Western's customer-first strategy, innovative leadership, and deep community roots GlobeNewswire July 07, 2025 HIGH RIVER, Alberta, July 07, 2025 (GLOBE NEWSWIRE) — Western Financial Group is proud to announce it has been named a recipient of the 2025 Canadian Business Excellence Award for Private

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia Regulatory momentum builds for bexobrutideg with multiple designations across the United States and EU, Including EMA PRIME and FDA Fast Track for CLL/SLL GlobeNewswire July 07, 2025 SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) —

Aya Gold & Silver Reports High-Grade Boumadine Exploration Results, Expands Imariren to 1km and Identifies New High-Grade Asirem Zone to the West

Aya Gold & Silver Reports High-Grade Boumadine Exploration Results, Expands Imariren to 1km and Identifies New High-Grade Asirem Zone to the West GlobeNewswire July 07, 2025 MONTREAL, July 07, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce new high-grade drill exploration results

Scroll to Top